

**Alameda Alliance for Health**  
1240 South Loop Road  
Alameda, CA 94502

**Piedmont Conference Room**  
To arrange public building access, please  
contact Ashley Ragadio at 510.373.5731

## AGENDA

ITEM	DESCRIPTION	TIME	VOTE
I)	<b>Call to order</b> <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i>	2 min	-
	<ul style="list-style-type: none"> <li>Conflict of Interest Check/Disclosure</li> <li>Agenda Overview</li> </ul>		
II)	<b>Informational Updates</b> <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>	15min	-
	<ul style="list-style-type: none"> <li>Pharmacy Carve Out</li> <li>NCQA update</li> </ul>		
III)	<b>Pharmacy Utilization Reports (Quarter 4)</b> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <i>Ramon Tran Tang, PharmD, Pharmacist – Alameda Alliance</i>		
	<ul style="list-style-type: none"> <li>Top 50 Drugs by Cost</li> <li>Top 100 PA Reviewed Drugs</li> <li>Emergency Room (ER) Report</li> </ul>		

### E-Voting Material/Consent Agenda

*Natalee Felten, PharmD, Pharmacist, PerformRx*

(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)

### The following items have been sent to the committee for review via E-Voting

Monographs/Class Reviews	Changes
Antispasmodics- GI class review	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Direct oral anticoagulants class review	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Medication Request Guidelines	Changes
Tolcapone (Tasmar)	<ul style="list-style-type: none"> <li>Add step therapy information for generic Stalevo and Comtan</li> <li>Change name from "tolcapone" to "Parkinson's disease"</li> </ul>
Antibiotic Eye Drops	<ul style="list-style-type: none"> <li>Add step therapy information for Ciloxan eye ointment</li> <li>Change name to "medications" instead of "drops" to be inclusive of ointment</li> </ul>
Tretinoin (Retin-A)	<ul style="list-style-type: none"> <li>Add step therapy information for generic Benzamycin gel</li> <li>Change the name from "tretinoin (Retin-A)" to "topical acne agents"</li> </ul>
Banzel (rufinamide)	<ul style="list-style-type: none"> <li>Update wording to account for liquid formulation</li> <li>Member must try and fail tablets prior to approval of liquid</li> </ul>

10  
min

**EV**  
(on  
each  
topic)

Rapid-Acting Insulin	<ul style="list-style-type: none"> <li>Inclusion of insulin lispro as non-formulary item.</li> <li>Removal of duplicate word in criteria section</li> </ul>
Modafinil and Armodafinil	<ul style="list-style-type: none"> <li>Re-order the way in which the bullet points display</li> </ul>
Ophthalmic Antihistamines	<ul style="list-style-type: none"> <li>Remove discontinued product Emadine</li> <li>Add in previously missing later approval duration (12 months)</li> </ul>
Synagis	<ul style="list-style-type: none"> <li>Correct spelling of November</li> <li>Update verbiage in the criteria statement for completeness</li> </ul>
Quantity Limit Exception	<ul style="list-style-type: none"> <li>Update formatting of bullets and spacing next to “OR”</li> </ul>
Cialis (tadalafil) for BPH	<ul style="list-style-type: none"> <li>Update brand generic status of Cialis</li> </ul>
Elmiron (pentosane polysulfate sodium)	<ul style="list-style-type: none"> <li>Re-order the way in which the bullet points display</li> </ul>
Symlin (pramlintide)	<ul style="list-style-type: none"> <li>Correct spelling of Apidra</li> </ul>
Atovaquone (Mepron)	<ul style="list-style-type: none"> <li>Removal of extra “reserved” in criteria statement</li> <li>Removal of extra space next to (PCP)</li> </ul>
Rifabutin (Mycobutin)	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Pyridostigmine (Mestinon)	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Tranexamic acid (Lysteda)	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Safety Edit Exception	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Altoprev (lovastatin ER) and	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Brilinta (ticagrelor) tablet	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Linezolid	<ul style="list-style-type: none"> <li>No changes</li> </ul>
<b>Interim Formulary changes</b>	
<ul style="list-style-type: none"> <li>See p. XX in packet</li> </ul>	
<b>Pharmacy Policies &amp; Procedures Updates</b>	
Policy & Procedure RX-002	<ul style="list-style-type: none"> <li>Biosimilar preferred</li> <li>30 day retro request</li> <li>How to submit a PA or Appeal</li> </ul>
Policy & Procedure RX-003	<ul style="list-style-type: none"> <li>Allow medically necessary drugs for COT instead of only single source.</li> </ul>
Policy & Procedure RX-009	<ul style="list-style-type: none"> <li>3 day ER override report</li> </ul>
Policy & Procedure RX-010	<ul style="list-style-type: none"> <li>Preventing Opioid Overutilization</li> </ul>
<b>P&amp;T Meeting Minutes</b>	
P&T Meeting Minutes Q4 December 17, 2019	

**ADJOURN TO CLOSED SESSION** (Pursuant to California Government Code Title 5, §54954.5(h))

*Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes*  
*Estimated Date of Public Disclosure: March 2020 (formulary changes only; no trade secrets will be disclosed).*

**IV) New Business**

*Natalee Felten, PharmD, Pharmacist, PerformRx*

*Rahel Negash, PharmD, Pharmacist – Alameda Alliance*

*Ramon Tran Tang, PharmD, Pharmacist – Alameda Alliance*

- Aptiom Medication Request Guideline
- Alprazolam Medication Request Guideline
- Corticosteroid Preparations to Treat Hemorrhoids Medication Request Guideline
- Diuretics Medication Request Guideline
- Antihypertensives Medication Request Guideline
- Fexofenadine 60 mg-pseudoephedrine ER Medication Request Guideline
- Minocycline Capsule Medication Request Guideline
- Savella Medication Request Guideline
- Travatan Z Eye Drops Medication Request Guideline
- Antibiotic Stewardship Program
- Physician Administered Drug (PAD) Medication Request Guideline Document

**Class Reviews, Monographs, and Recommendations**

*Natalee Felten, PharmD, Pharmacist, PerformRx*

*Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance*

1. First generation antihistamines class review
2. Inhaled anticholinergics class review
3. Vasodilators-direct and coronary class review
4. Pulmonary biologics class review
5. Idiopathic pulmonary fibrosis class review
6. Cystic fibrosis class review
7. Androgens testosterone agents class review
8. Glucagon comparative review
9. Oxbryta monograph
10. Rybelsus monograph

60  
min

V

**RECONVENE IN OPEN SESSION**

ITEM	DESCRIPTION	TIME	VOTE	
V)	<b>Summary of Closed Session</b> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>	2 min	-	
VI)	<b>Medication Request Guidelines Updates</b> <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i>			
	1. Self-administered Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS) (10 min inc			
	2. Healthcare professional (HCP) administered/IV Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS)			
	3. Pulmonary Arterial Hypertension (PAH) Criteria			
	4. Medications for the treatment of Multi-Drug Resistant Tuberculosis			
	5. Thrombocytopenia Agents	10	V	
	6. Low Molecular Weight Heparins	min		
	7. Drugs for Gender Dysphoria For Less Than 21 Years Old			
	8. Drugs for Gender Dysphoria For At Least 21 Years Old			
	9. Estrogen Patches and Injectable			
	10. Ezetimibe (Zetia)			
	11. Injectable/Specialty Medications			
	12. Oral and Injectable Oncology Medications			
	13. Brand Medications When a Generic Available			
VII)	<b>Informational Updates on New Developments in Pharmacy</b> <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i>			-
	• New Product Review (2 min)			
VIII)	<b>Old Business</b> <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i>			
	• Generic Renagel vs generic Renvela cost comparison (2min)			
IX)	<b>Public Comment</b>	2 min	-	
X)	<b>Adjournment</b>			
	• P&T Committee Member Forms	-	-	

**ACTION / FOLLOW-UP ITEMS**

ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS	
NEXT MEETING	2020 P&T MEETINGS
June 16th, 2020	June 16 <sup>th</sup> , 2020
	September 15 <sup>th</sup> , 2020
	December 15 <sup>th</sup> , 2020

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

**Note:** Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or [hlee@alamedaalliance.org](mailto:hlee@alamedaalliance.org) at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.